Outsourced Pharma White Papers

  1. The Key To Viral Vector Success 11/11/2024

    Establishing a robust and scalable viral vector process requires a multidisciplinary approach that incorporates expertise in foundational science, analytics, and biomanufacturing.

  2. Clear MRSA Infections At Single Low Doses 1/4/2024

    Multidrug-resistant bacteria are rendering antibiotics ineffective. Review preclinical results of a potent macrocycle derivative and why collaboration is crucial to transition discoveries into treatments.

  3. Tablet Manufacturing Technologies For Solid Drug Formulation 4/2/2025

    Compressed tablets are common oral solid dosages that contain the API and various excipients. Learn about the critical steps in selecting manufacturing methods and excipients to achieve the desired therapeutic effects and stability.

  4. The Benefits Of Incorporating Lean Methodologies Into Project Management 8/20/2024

    Delve into the core principles of lean project management and explore how these principles can be integrated with traditional methods to enhance project outcomes.

  5. Safety, Containment, And Analysis Of Highly Potent Compounds 5/16/2024

    Explore a comprehensive overview of the challenges, requirements, and best practices for safely working with highly potent compounds in drug development and manufacturing.

  6. Biomanufacturing Readiness: A Validation Model For Multiproduct Facilities 6/12/2025

    Optimize your validation strategy to meet evolving regulatory demands and product complexities with a scalable, efficient framework that accelerates facility readiness and ensures consistent quality.

  7. Optimizing Reference Standards For Your Biopharmaceutical 1/29/2024

    By addressing considerations for a comprehensive reference standard strategy, manufacturers can ensure the integrity of biopharmaceuticals, ultimately paving the way for better patient outcomes.

  8. Cell Line Development: The Linchpin In Biotherapeutic Development 1/4/2024

    Review key factors for building a reliable CLD strategy, and learn how the right CDMO can help you achieve the high quality, high yield, and speed needed to successfully bring a biologic to market.

  9. A New Framework For Identifying Nitrosamine Risks And Derisking Products 6/18/2024

    Examine a new methodology that holds significant promise for identifying APIs at risk for NDSRI formation, enabling manufacturers to prioritize risk mitigation strategies and ensure compliance.

  10. Optimizing Charge And N-glycan Profiles For CHO-Derived Fusion Proteins 9/24/2025

    Discover how structured design-of-experiment approaches can optimize charge variants and glycosylation to enhance biologics quality and therapeutic performance.